Theratope: Phase II completed enrollment

BIOM completed enrollment of 95 patients in a single-arm U.S. Phase II trial of Theratope in combination with an aromatase inhibitor or Faslodex fulvestrant from AstraZeneca plc (LSE:AZN; AZN, Lond...